Category Archives: Parkinson’s Treatment

67 WALL STREET, New York - August 22, 2013 - The Wall Street Transcript has just published its Water Services Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Water Infrastructure Development - Irrigation and Metering Technology - Water Industry Consolidation - Regulatory Headwinds for U.S. Utilities Companies include: Nuverra Environmental Solutions, Inc. (NES) and many more. In the following excerpt from the Water Services Report, the Executive Vice President and CFO of Nuverra Environmental Solutions, Inc. (NES) discusses company strategy and the outlook for this vital industry: TWST: You offer solutions in several different areas, including environmental, shale and industrial. Can you please explain the solutions in each of those segments, and tell us how they are different? Mr. Parkinson: Basically we are an environmental solutions company that operates essentially in two end markets. The first is in unconventional shale basins, the oil and gas basins, and the second is a business that focuses more on the industrial end … Continue reading →

67 WALL STREET, New York - August 22, 2013 - The Wall Street Transcript has just published its Water Services Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Water Infrastructure Development - Irrigation and Metering Technology - Water Industry Consolidation - Regulatory Headwinds for U.S. Utilities Companies include: Nuverra Environmental Solutions, Inc. (NES) and many more. In the following excerpt from the Water Services Report, the Executive Vice President and CFO of Nuverra Environmental Solutions, Inc. (NES) discusses company strategy and the outlook for this vital industry: TWST: You offer solutions in several different areas, including environmental, shale and industrial. Can you please explain the solutions in each of those segments, and tell us how they are different? Mr. Parkinson: Basically we are an environmental solutions company that operates essentially in two end markets. The first is in unconventional shale basins, the oil and gas basins, and the second is a business that focuses more on the industrial end … Continue reading →

Parkinson's Breakthrough The words of one young mother, diagnosed with a life-altering disease, provide the framework for a story on a new scientific discovery that could lead to a c... By: Johnson Reports … Continue reading →

Bettering Life with Parkinson's Jerry Bramlett is among the one million people in the U.S. who is living life with Parkinson's disease. "I started progressing with Parkinson's when I was in... By: LeeMemorialMarketing … Continue reading →

By Simon Cable PUBLISHED: 06:02 EST, 18 August 2013 | UPDATED: 09:51 EST, 19 August 2013 Recovering well: Legendary TV host Michael Parkinson has finished his treatment for cancer Sir Michael Parkinson has been told he can expect to make a full recovery from prostate cancer. The 78-year-old TV host has completed a month of intensive radiotherapy, and is now awaiting test results. He is recovering at his home in Berkshire with his wife Mary. The couples son, Mike, said it was early days, but added: The prognosis is good. Everything went to plan and now it is a case of rest and recuperation for a month or so. My dads in good spirits and he is expected to make a full recovery. Sir Michael, affectionately known as Parky, interviewed around 2,000 celebrities over four decades, ranging from Madonna to Muhammad Ali. He was diagnosed with prostate cancer in May and went public with the news in July. Since then he has worked to raise awareness of the disease, launching a campaign urging men to check for warning signs. Read more: Sir Michael Parkinson expecting full recovery after completing treatment for prostate cancer … Continue reading →

Q: My father was diagnosed with Parkinson's last year. His medication controls the tremors, but when he forgets his pills, he shuffles and suffers. Would deep brain stimulation zap his disease? A: Deep brain stimulation is a surgical option; a neurostimulator, implanted in the chest, delivers electrical signals to the brain, much like a pacemaker. In Parkinson's, the device is linked to electrodes that are implanted in the areas of the brain that control movement. This is a great treatment for some patients, but not all. It does not cure the disease or stop the progression; it just helps control some of the symptoms. Stimulation is helpful for patients who have a tremor that is not controlled well enough with medication, or who have side effects from medicine. It does not alleviate other symptoms, such as balance and memory problems, and can even worsen them. In general, we make sure to exhaust all drug options before referring to surgery, since all surgeries entail risk. Every case is different; a decision to operate should be made with the guidance of a specialist who knows the patient well. Since your father responds well to pills, but has trouble remembering them, use an … Continue reading →

Public release date: 16-Aug-2013 [ | E-mail | Share ] Contact: Jeffrey Norris jeff.norris@ucsf.edu 415-502-6397 University of California - San Francisco UC San Francisco scientists working in the lab used a chemical found in an anti-wrinkle cream to prevent the death of nerve cells damaged by mutations that cause an inherited form of Parkinsons disease. A similar approach might ward off cell death in the brains of people afflicted with Parkinsons disease, the team suggested in a study reported online in the journal Cell on August 15. The achievement marks a pharmacologic milestone as the first highly specific targeting of a member of an important class of enzymes called kinases to increase rather than to inhibit their activity, according to UCSF chemist Kevan Shokat, PhD, the senior scientist on the study. The research raises hope that similar pharmaceutical strategies might be used for combatting other diseases, including diabetes and cancer, he said. Mutations that cause malfunction of the targeted enzyme, PINK1, are directly responsible for some cases of early-onset Parkinsons disease. Loss of PINK1 activity is harmful to the cells power plants, called mitochondria, best known for converting food energy into another form of chemical energy used by cells, the … Continue reading →

Newswise STRATFORD, NJ The Michael J. Fox Foundation for Parkinsons Research has awarded Durin Technologies, Inc., a grant of $351,200 to expand the development of Durins novel blood test that can detect the presence of Parkinsons disease. The test was created by Robert Nagele, PhD, a professor of medicine and the director of the Biomarker Discovery Center at the Rowan University School of Osteopathic Medicine, and the founder of Durin Technologies. In a pilot study published last year, the test was remarkably accurate (93.1 percent sensitivity and 100 percent specificity) in detecting specific autoantibody biomarkers that indicate the presence of Parkinsons disease. Using current diagnostic methods, it can take months or even years to make an accurate Parkinsons diagnosis, and by that time, at least a third of the neurons in the affected area of the brain will have already died, Nagele said. A reliable blood test for Parkinsons would have a huge impact on patient care and on research into potential disease-modifying medications. Without the support of The Michael J. Fox Foundation, however, we would be hard pressed to find the resources that would enable us to move this technology forward. The reliance on clinical observation of Parkinsons disease … Continue reading →

A Christian Science perspective. My world got smaller four simple words from a father in New Zealand to explain in a poem to his children how he felt after being diagnosed with Parkinsons disease. Subscribe Today to the Monitor Click Here for your FREE 30 DAYS of The Christian Science Monitor Weekly Digital Edition Many more have gained some sense of the effect of this condition from Michael J. Fox, star of the Back to the Future trilogy. He became the most famous face of the disease when he disclosed his condition in 1998 and launched a successful Foundation for Parkinsons Research two years later. Wittily terming himself an incurable optimist, the actors world looks far from smaller. In addition to being a father of four and directing his primary focus and energies toward his foundation, Mr. Fox continues acting, has written bestselling books, and is launching a sitcom in which he plays a newsman persuaded to return to work despite having Parkinsons. Beyond that continuing career trajectory, Fox exudes qualities that inspire: humor, commitment, humility, generosity, love, and that optimism. These are indomitable spiritual qualities that truly define us all. Perhaps theyre the kind of qualities that that New … Continue reading →

Research has linked the disease to a genetic defect that stops cells clearing out defective mitochondria, tiny metabolic generators that supply energy. Dysfunctional mitochondria can be very harmful. Cells normally dispose of them through a process called mitophagy that breaks them down. Scientists have now discovered a biological pathway that allows mutations in a gene called FBxo7 to interfere with mitophagy. In people with Parkinson's, this causes a build-up of defective mitochondria that may kill brain cells. A study published in the journal Nature Neuroscience indicates mitophagy might be the key to new treatments for the disease. Dr Helene Plun-Favreau, one of the researchers from the University College London Institute of Neurology, said: "Treatment strategies that target mitophagy might be developed to benefit patients with Parkinson's disease in the future. "What makes the study so robust is the confirmation of defective mitophagy in a number of different Parkinson's models." Professor Hugh Perry, chair of the neurosciences and mental health board at the Medical Research Council which part-funded the study, said the work raised interesting questions about brain-cell death related to Parkinson's. He added: "The more we understand about the basic molecular events which contribute to the onset and progression of … Continue reading →